S
Shanghai Likai Technology
Clinically proven neurovascular interventional and implantable medical devices
About Shanghai Likai Technology
Kai MedTech Inc., also known as Shanghai Likai Technology, develops and commercializes interventional and implantable medical devices for treating neurovascular diseases. The company was founded in 2019 by Chairman Jianbing Wang. Wang previously founded MicroVention in 1997, which was later acquired by Terumo Corporation.
Read full description
Kai MedTech operates with a vision of creating an innovative medical device platform. It maintains a portfolio of products and has established three research and development and manufacturing sites located in Lake Forest, California, USA; Shanghai, China; and Hangzhou, China. The company's business model is centered on the development and sale of these medical devices to the healthcare sector.
As of March 31, 2023, the company has commercialized nine NMPA Class III products in China and one product with US FDA 510(k) clearance. Its product pipeline includes devices like the ReviveFlow™ Revascularization Device and the Perfiller® Embolic Coil, designed for procedures such as mechanical thrombectomy and aneurysm treatment.
Latest news
Press, funding announcements and product moves mentioning Shanghai Likai Technology.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES D✓Equity / VC | Jul 2026 | $69M | $275M | Shenzhen Capital Group · Huatai Zijin Investment | ↗ |
| SERIES D✓Equity / VC | Feb 2026 | — | — | Guoxin Investment | ↗ |
Growth signals
Latest recorded traffic for Shanghai Likai Technology is 20K monthly website visits, up 5614.3% over the last three months. Shanghai Likai Technology's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later4 investors entered at this stage
- GIGuoxin Investment
Wuxi Innovation Investment Group
Shenzhen Capital Group
Huatai Zijin Investment
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Shanghai Likai Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shanghai Likai Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







